2024
Leriglitazone has met the primary endpoint in NEXUS, the pivotal trial for pediatric patients with cerebral Adrenoleukodystrophy
11/12/2024Statistically significant difference in arrested disease in leriglitazone treated patients when compared to the natural history of the disease.
Read More
Buenavista Equity Partners, together with Columbus Venture Partners, completes first €100mn closing for its healthcare fund
09/12/2024The fund, Healthcare Growth Innvierte I, has raised commitments of €100 million for this new healthcare strategy, having already reached its target size.
This new initiative is a joint venture between Columbus VP, a specialist in biotech venture operations, and Buenavista.
Read More
Aura announced positive early data from an ongoing Phase 1 clinical trial of bel-sar (AU-011) in patients with non-muscle-invasive bladder cancer
21/10/2024Clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. Our lead candidate, bel-sar (AU-011), is currently in late-stage development for primary choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer.
Read More
ARTHEx Biotech Announces First Patient Dosed in Phase I-IIa ArthemiR™ Trial for Myotonic Dystrophy Type 1 (DM1)
21/10/2024Clinical-stage biotechnology company focused on developing innovative medicines through the modulation of gene expression. The Company’s lead investigational compound, ATX-01, is being evaluated for the treatment of myotonic dystrophy type 1 (DM1), a rare neuromuscular disorder, in the Phase I-IIa ArthemiR™ trial.
Read More
Tolerance Bio, Inc. Launches with $17.2 Million in Seed Financing to Advance Thymus-Based Therapies for Immune-Mediated Diseases
15/10/2024Led by industry innovator Francisco Leon, M.D., Ph.D., Tolerance Bio is developing thymus preservation, regeneration, and manipulation platforms to prevent and treat immune diseases. Financing led by Columbus Venture Partners.
Read More
Cocoon Bioscience has inaugurated the first industrial production plant for recombinant proteins using living bioreactors in Euskadi, Spain
30/09/2024Cocoon Bioscience has inaugurated the world’s first industrial-scale production plant for recombinant proteins using living bioreactors in Euskadi, Spain. This groundbreaking facility utilizes insects in their chrysalis stage as low-cost natural bioreactors for protein production.
Read More
Dr Gloria Gonzalez-Aseguinolaza, Chief Scientific Officer of Vivet Therapeutics Receives the Rosalind Franklin Society Special Award in Science
18/07/2024Congratulations to the Co-Founder and Chief Scientific Officer, Gloria Gonzalez-Aseguinolaza who has been honored with the prestigious Rosalind Franklin Society (RFS) Special Award in Science for her remarkable contributions and dedication to advancing scientific knowledge.
Read More
Integra Therapeutics receive up to €10.5 million from European Commission for its FiCAT advanced therapies platform
18/07/2024Integra Therapeutics, backed by Columbus and Invivo, receive up to €10.5 million from European Commission for its FiCAT advanced therapies platform.
Read More
Leriglitazone halts disease progression in adult patients with early cerebral adrenoleukodystrophy in compassionate-use study published in Brain
11/06/2024Minoryx announces that results from a compassionate use study of leriglitazone for treatment of progressive cerebral adrenoleukodystrophy (cALD) in adult male patients was published in the peer-reviewed journal Brain.
Read More
Syngoi Technologies Expands Synthetic DNA Manufacturing Capacity Following Series B Investment Led by Columbus Venture Partners
10/06/2024We’re thrilled to announce that Syngoi Technologies has significantly expanded its synthetic DNA manufacturing capacity, thanks to a successful Series B investment round led by COLUMBUS VP. Asahi Kasei Medical has joined Columbus VP in this strategic investment.
Read More